Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CD33CAR-CD3zeta-4-1BB-expressing T lymphocytes

A preparation of allogeneic T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the CD33 antigen, coupled to the signaling domain of 4-1BB (CD137) and the zeta chain of the T-cell receptor (TCRzeta), with potential immunomodulating and antineoplastic activities. Upon administration, allogeneic CD33CAR-CD3zeta-4-1BB-expressing T lymphocytes target and induce selective toxicity in CD33-expressing tumor cells. CD33 is expressed on normal non-pluripotent hematopoietic stem cells and on myeloid leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic anti-CD33 CAR-CD3zeta-4-1BB-expressing T cells
allogeneic anti-CD33-CAR-CD3zeta-4-1BB-expressing T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search